Advanced Oncotherapy (LON:AVO) goal is to deliver an affordable and novel proton therapy system (PT), based on state-of-the-art technology developed originally at the world-renowned CERN. Achievement of major technical milestones
City of London Investment Group Plc (LON:CLIG) has released its trading update for 1Q of FY’19. The statement shows a continuation of the trends seen in recent statements. Aggregate inflows
The wit of Mauricio Pochettino “It’s like the cow that every single day during 10 years sees the train crossing in front of it at the same time. And if
Warpaint London Plc (LON:W7L) interim results for the six months ending June 2018 showed revenue up 38.7% to £18.4m (1H’17: £13.3m). The company’s two divisions, own-brand and close-out, represented 84%
Burford Capital (LON:BUR) has placed 10.41m new shares with institutional investors through an accelerated bookbuild. The price per share was 1850p, making a total of £192.6m ($251.2m) raised before expenses.
Redx Pharma Plc (LON:REDX) new management team is continuing to focus its financial resources on progressing its lead candidates in oncology and fibrotic disease into the clinic. When the first
Oxford BioMedica (LON:OXB) is a specialist, advanced-therapy, lentivirus vector biopharma company. It offers vector manufacturing and development services and has a proprietary drug pipeline. In addition to LentiVector® service contracts,
The 600 Group (LON:SIXH) remains competitively well positioned, with a world-class reputation in Machine Tools and Laser Marking. 65% of sales are in the US. Business momentum is healthy, with
The turnaround of International Lithium Corp. (LON:ILC) has taken its first steps under the stewardship of a new Chairman/CEO appointed in March 2018. At the same time, the company continues
Arbuthnot Banking Group (LON:ARBB) is delivering the strong profit and franchise growth that had been promised, with underlying profits rising from £3.2m in 1H’17 to £4.2m in 1H’18. We now
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
